Edding Genor Group Holdings Limited
6998.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.38B
Close$
$0.25
85.1% downside
Current Fair Value
85.1% downsideOvervalued by 85.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.38 Billion |
|---|---|
| Enterprise Value | $3.65 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.23 |
| Beta | 0.9 |
| Outstanding Shares | 1,998,143,726 |
Return
| Return on Equity | 23.61% |
|---|---|
| Return on Assets | 15.43% |
| Return on Invested Capital | 43.93% |
Valuation & Multiples
| P/E Ratio | 4.71 |
|---|---|
| PEG | 36.07 |
| Price to Sales | 0.56 |
| Price to Book Ratio | 1.69 |
| Enterprise Value to Revenue | 0.58 |
| Enterprise Value to EBIT | 2 |
| Enterprise Value to Net Income | 3 |
| Total Debt to Enterprise | 0.32 |
| Debt to Equity | 0.3 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
$-1.50
Average shareholder expectationRevenue Estimate
$5.40 M
Average shareholder expectationNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
$-0.56
Average shareholder expectationRevenue Estimate
$8.06 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Edding Genor Group Holdings Limited
1,499 employees
CEO: Xin Ni Genor Biopharma Holdings Limited operates as a biopharmaceutical enterprise, concentrating its efforts on the research, development, and commercialization of therapeutic agents for oncology and autoimmune disorders, both within China and...